<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03047681</url>
  </required_header>
  <id_info>
    <org_study_id>0678-15-TLV</org_study_id>
    <nct_id>NCT03047681</nct_id>
  </id_info>
  <brief_title>Tryptase Level as a Marker of Complications in Transcatheter Aortic Valve Replacement</brief_title>
  <acronym>TAVR</acronym>
  <official_title>Tryptase Levels as a Marker of Mast Cell Activity and the Prognostic Implication in Patients Post Transcatheter Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An association between mast cells and outcomes of patients undergoing transcatheter aortic&#xD;
      valve replacement (TAVR) has not been studied to our knowledge. We aim to characterize&#xD;
      tryptase levels dynamics during TAVR; Demonstrate whether tryptase level post-TAVR can be&#xD;
      used as a prognostic marker.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammation is known to have a detrimental effect on outcome of patients with myocardial&#xD;
      infarction (MI) [1, 2] as well as reperfusion injury (RI) [3]. Previous trials have shown&#xD;
      correlation between the extent of an inflammatory response and postoperative complications&#xD;
      and worse outcomes in patients undergoing cardiac surgery [4, 5, 6, 7] including valve&#xD;
      replacement [8]. Transcatheter aortic valve replacement (TAVR) may be associated with&#xD;
      inflammation [5, 9] as well. A few possible mechanisms may be responsible, such as tissue&#xD;
      injury due to mechanical trauma, vascular complications, and possible suboptimal organ&#xD;
      perfusion due to bleeding, ventricular pacing, balloon valvuloplasty, deployment,&#xD;
      post-dilatation, or repositioning of the valve prosthesis [10]. Accumulating data show that&#xD;
      peri-procedural inflammation is associated with worse outcomes and complications of TAVR [11,&#xD;
      12, 13, 14, 15], and may predict increased mortality in patients after TAVR [16, 17, 18, 19,&#xD;
      20].&#xD;
&#xD;
      Inflammation is a complex process and includes many types of cells including mast cells. The&#xD;
      association between mast cells, as part of the inflammatory process, and RI has been&#xD;
      thoroughly studied. Mast cells have been linked to RI in many organs [21], contributing to&#xD;
      insult to the myocardium. This association has been suggested from animal models [22, 23, 24]&#xD;
      as well as recent human trials which showed that tryptase, an abundant protease found in mast&#xD;
      cell granules, is elevated in ST segment elevation myocardial infarction (STEMI) patients&#xD;
      treated with primary percutaneous coronary intervention (PCI) [25].&#xD;
&#xD;
      Therefore, it is reasonable to assume that mast cells may have a role in the inflammation&#xD;
      process involved in patients undergoing TAVR. Moreover, such association with mast cells may&#xD;
      be used to predict adverse outcomes.&#xD;
&#xD;
      To our knowledge, an association between mast cells and outcomes of patients undergoing TAVR&#xD;
      has not been studied.&#xD;
&#xD;
      METHODS Peripheral venous blood from 30 patients undergoing TAVR will be withdrawn to examine&#xD;
      tryptase levels, as a marker of mast cell activity. Blood samples will be taken at 0 hours&#xD;
      (before the procedure) and a second sample will be taken up to 2 hours post-procedure.&#xD;
&#xD;
      CRP will be examined in each patient pre and post TAVR. Tryptase levels will be examined in&#xD;
      10 patients undergoing diagnostic coronary angiography.&#xD;
&#xD;
      PRIMARY OBJECTIVE We aim to: 1. Characterize tryptase levels dynamics during TAVR 2.&#xD;
      Demonstrate whether tryptase level post-TAVR can be used as a prognostic marker.&#xD;
&#xD;
      Primary outcome - mortality at 1 year Secondary outcomes - Major complications at 7 days and&#xD;
      30 days, including death, major stroke, acute kidney injury, paravalvular regurgitation,&#xD;
      permanent pacemaker implantation, coronary artery obstruction, heart block, vascular injury,&#xD;
      pericardial hemorrhage.&#xD;
&#xD;
      REFERENCES:&#xD;
&#xD;
        1. Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tasissa G, Hochman JS, Todaro TG, Malloy&#xD;
           KJ, Rollins S, Theroux P, Ruzyllo W, Nicolau JC, Granger CB. Prognostic usefulness of&#xD;
           white blood cell count and temperature in acute myocardial infarction (from the CARDINAL&#xD;
           Trial). Am J Cardiol 2005;95:614-618.&#xD;
&#xD;
        2. Theroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, Nicolau JC,&#xD;
           Lavoie J, Luong TM, Burchenal J, Granger CB. Prognostic significance of blood markers of&#xD;
           inflammation in patients with ST-segment elevation myocardial infarction undergoing&#xD;
           primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA&#xD;
           trial. Eur Heart J 2005;26:1964-1970.&#xD;
&#xD;
        3. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial&#xD;
           ischemia/reperfusion injury. J Am Coll Cardiol. 2015 Apr 14;65(14):1454-71.&#xD;
&#xD;
        4. Cremer J, Martin M, Redl H, Bahrami S, Abraham C, Graeter T, Haverich A, Schlag G, Borst&#xD;
           HG. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg&#xD;
           1996;61:1714-1720.&#xD;
&#xD;
        5. Lindman BR, Goldstein JS, Nassif ME, Zajarias A, Novak E, Tibrewala A, Vatterott AM,&#xD;
           Lawler C, Damiano RJ, Moon MR, Lawton JS, Lasala JM, Maniar HS. Systemic inflammatory&#xD;
           response syndrome after transcatheter or surgical aortic valve replacement. Heart 2015&#xD;
           Apr;101(7):537-45.&#xD;
&#xD;
        6. Kilger E, Heyn J, Beiras-Fernandez A, et al. Stress doses of hydrocortisone reduce&#xD;
           systemic inflammatory response in patients undergoing cardiac surgery without&#xD;
           cardiopulmonary bypass. Minerva Anestesiol. 2011;77:268-274.&#xD;
&#xD;
        7. Clarizia NA, Manlhiot C, Schwartz SM, et al. Improved outcomes associated with&#xD;
           intraoperative steroid use in high-risk pediatric cardiac surgery. Ann Thorac Surg.&#xD;
           2011;91(4):1222-1227.&#xD;
&#xD;
        8. Prat C, Ricart P, Ruyra X, et al. Serum concentrations of procalcitonin after cardiac&#xD;
           surgery. J Card Surg. 2008;23(6):627-632.&#xD;
&#xD;
        9. Stähli BE1, Grünenfelder J, Jacobs S, Falk V, Landmesser U, Wischnewsky MB, Lüscher TF,&#xD;
           Corti R, Maier W, Altwegg LA. Assessment of inflammatory response to transfemoral&#xD;
           transcatheter aortic valve implantation compared to transapical and surgical procedures:&#xD;
           a pilot study. J Invasive Cardiol. 2012 Aug;24(8):407-11.&#xD;
&#xD;
       10. Sinning JM1, Scheer AC, Adenauer V, Ghanem A, Hammerstingl C, Schueler R, Müller C,&#xD;
           Vasa-Nicotera M, Grube E, Nickenig G, Werner N. Systemic inflammatory response syndrome&#xD;
           predicts increased mortality in patients after transcatheter aortic valve implantation.&#xD;
           Eur Heart J. 2012 Jun;33(12):1459-68.&#xD;
&#xD;
       11. Masson JB1, Kovac J, Schuler G, Ye J, Cheung A, Kapadia S, Tuzcu ME, Kodali S, Leon MB,&#xD;
           Webb JG. Transcatheter aortic valve implantation: review of the nature, management, and&#xD;
           avoidance of procedural complications. JACC Cardiovasc Interv. 2009 Sep;2(9):811-20.&#xD;
&#xD;
       12. Toggweiler S1, Webb JG. Challenges in transcatheter aortic valve implantation. Swiss Med&#xD;
           Wkly. 2012 Dec 17;142:w13735.&#xD;
&#xD;
       13. Rettig TC1, Rigter S1, Nijenhuis VJ2, van Kuijk JP2, ten Berg JM2, Heijmen RH3, van de&#xD;
           Garde EM4, Noordzij PG. The systemic inflammatory response syndrome predicts short-term&#xD;
           outcome after transapical transcatheter aortic valve implantation. J Cardiothorac Vasc&#xD;
           Anesth. 2015 Apr;29(2):283-7.&#xD;
&#xD;
       14. Krumsdorf U1, Chorianopoulos E, Pleger ST, Kallenbach K, Karck M, Katus HA, Bekeredjian&#xD;
           R. C-reactive protein kinetics and its prognostic value after transfemoral aortic valve&#xD;
           implantation. J Invasive Cardiol. 2012 Jun;24(6):282-6.&#xD;
&#xD;
       15. Van Linden A1, Kempfert J, Rastan AJ, Holzhey D, Blumenstein J, Schuler G, Mohr FW,&#xD;
           Walther T. Risk of acute kidney injury after minimally invasive transapical aortic valve&#xD;
           implantation in 270 patients. Eur J Cardiothorac Surg. 2011 Jun;39(6):835-42; discussion&#xD;
           842-3.&#xD;
&#xD;
       16. Zahn R, Gerckens U, Grube E, Linke A, Sievert H, Eggebrecht H, Hambrecht R, Sack S,&#xD;
           Hauptmann KE, Richardt G, Figulla HR, Senges J. Transcatheter aortic valve implantation:&#xD;
           first results from a multi-centre real-world registry. Eur Heart J 2011;32:198-204&#xD;
&#xD;
       17. Sinning JM, Ghanem A, Steinhauser H, Adenauer V, Hammerstingl C, Nickenig G, Werner N.&#xD;
           Renal function as predictor of mortality in patients after percutaneous transcatheter&#xD;
           aortic valve implantation. JACC Cardiovasc Interv 2010;3:1141-1149.&#xD;
&#xD;
       18. Nuis RJ, van Mieghem NM, Tzikas A, Piazza N, Otten AA, Cheng J, van Domburg RT, Betjes&#xD;
           M, Serruys PW, de Jaegere PP. Frequency, determinants and prognostic effects of acute&#xD;
           kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic&#xD;
           valve implantation. Catheter Cardiovasc Interv 2011;77:881-889.&#xD;
&#xD;
       19. Aregger F, Wenaweser P, Hellige GJ, Kadner A, Carrel T, Windecker S, Frey FJ. Risk of&#xD;
           acute kidney injury in patients with severe aortic valve stenosis undergoing&#xD;
           transcatheter valve replacement. Nephrol Dial Transplant 2009;24:2175-2179.&#xD;
&#xD;
       20. Bagur R, Webb JG, Nietlispach F, Dumont E, De Larochelliere R, Doyle D, Masson JB,&#xD;
           Gutierrez MJ, Clavel MA, Bertrand OF, Pibarot P, Rodes-Cabau J. Acute kidney injury&#xD;
           following transcatheter aortic valve implantation: predictive factors, prognostic value,&#xD;
           and comparison with surgical aortic valve replacement. Eur Heart J 2010;31:865-874. Van&#xD;
           Linden A, Kempfert J, Rastan AJ, Holzhey D, Blumenstein J, Schuler G, Mohr FW, Walther&#xD;
           T. Risk of acute kidney injury after minimally invasive trans-apical aortic valve&#xD;
           implantation in 270 patients. Eur J Cardiothorac Surg 2011;39:835-42.&#xD;
&#xD;
       21. Yang MQ1, Ma YY, Ding J, Li JY. The role of mast cells in ischemia and reperfusion&#xD;
           injury. Inflamm Res. 2014 Nov;63(11):899-905.&#xD;
&#xD;
       22. Masini E, Giannella E, Bianchi S, Mannaioni PF: Histamine and lactate dehydrogenase&#xD;
           (LDH) release in ischemic myocardium of the guinea-pig. Agents Actions 1987;20:281-283.&#xD;
&#xD;
       23. Masini E1, Bianchi S, Gambassi F, Palmerani B, Pistelli A, Carlomagno L, Mannaioni PF.&#xD;
           Ischemia reperfusion injury and histamine release in isolated and perfused guinea-pig&#xD;
           heart: pharmacological interventions. Agents Actions. 1990 Apr;30(1-2):198-201&#xD;
&#xD;
       24. Frangogiannis NG1, Perrard JL, Mendoza LH, Burns AR, Lindsey ML, Ballantyne CM, Michael&#xD;
           LH, Smith CW, Entman ML. Stem cell factor induction is associated with mast cell&#xD;
           accumulation after canine myocardial ischemia and reperfusion. Circulation. 1998 Aug&#xD;
           18;98(7):687-98.&#xD;
&#xD;
       25. Shaomin Chen, Di Mu, Ming Cui, Chuan Ren, Shu Zhang, Lijun Guo, and Wei Gao. Dynamic&#xD;
           changes and clinical significance of serum tryptase levels in STEMI patients treated&#xD;
           with primary PCI. Biomarkers. 2014 Nov;19(7):620-4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">February 2017</start_date>
  <completion_date type="Anticipated">December 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>7 and 30 days</time_frame>
    <description>mortality at 7 and 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Post procedural complications - major stroke, acute kidney injury, paravalvular regurgitation, permanent pacemaker implantation, coronary artery obstruction, heart block, vascular injury, pericardial hemorrhage</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Transcatheter Aortic Valve Implantation Prosnosis and Complications</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>patients undergoin transcatheter aortic valve implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>patient undergoing diagnostic coronary angiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>venous blood withdrawl</intervention_name>
    <description>patients will be asked for a venous blood sample</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tryptase level in serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who undergo TAVR&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  Capable of giving informed consent&#xD;
&#xD;
          -  Undergoing TAVR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zach Rozenbaum, MD</last_name>
      <phone>972-3-6973313</phone>
      <email>zachr@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Zach Rozenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVR</keyword>
  <keyword>tryptse</keyword>
  <keyword>mast</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only the principle investigator will have access to IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

